Literature DB >> 22664935

Impact of metabolic syndrome on various aspects of microcirculation and major adverse cardiac events in patients with ST-segment elevation myocardial infarction.

Yasuhiro Uchida1, Satoshi Ichimiya, Hideki Ishii, Masaaki Kanashiro, Junji Watanabe, Daiji Yoshikawa, Kyosuke Takeshita, Shinichi Sakai, Tetsuya Amano, Tatsuaki Matsubara, Toyoaki Murohara.   

Abstract

BACKGROUND: Microvascular impairment is associated with a poor prognosis even after successful percutaneous coronary intervention (PCI) in acute myocardial infarction. The aim of the present study was to examine the impact of metabolic syndrome (MetS) on various aspects of microvascular function and clinical outcomes. METHODS AND
RESULTS: In 216 consecutive patients with ST-segment elevation myocardial infarction (STEMI) after successful primary PCI, data were collected and analyzed on epicardial coronary flow, ST-segment resolution (STR) on electrocardiography, maximum serum creatine kinase levels, and the incidence of major adverse cardiac events (MACE). The prevalence of MetS was 40.7% (88 patients). Corrected Thrombolysis In Myocardial Infarction frame count was significantly higher in the MetS group than in the non-MetS group (28.1±9.4 vs. 24.7±7.9, P=0.04). STR ≥50% was observed in 51.1% and 69.5%, respectively (P=0.01). Patients with MetS also had higher maximum creatine kinase levels (3,470±2,320IU/L vs. 2,664±1,850IU/L, P=0.01). On logistic regression analysis after adjustment for confounders, MetS was an independent negative predictor of complete STR (odds ratio, 0.49; 95% confidence interval [CI]: 0.25-0.95, P=0.03). On Cox multivariate analysis, MetS was an independent predictor for MACE (hazard ratio, 4.85; 95% CI: 1.28-18.3, P=0.02).
CONCLUSIONS: MetS may damage microcirculation after direct PCI in patients with STEMI and lead to poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22664935     DOI: 10.1253/circj.cj-11-1299

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  8 in total

1.  Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease.

Authors:  Arwa Younis; Anan Younis; Boaz Tzur; Yael Peled; Nir Shlomo; Ilan Goldenberg; Enrique Z Fisman; Alexander Tenenbaum; Robert Klempfner
Journal:  Cardiovasc Diabetol       Date:  2016-10-28       Impact factor: 9.951

2.  Selective intrarenal delivery of mesenchymal stem cell-derived extracellular vesicles attenuates myocardial injury in experimental metabolic renovascular disease.

Authors:  Lei Zhang; Xiang-Yang Zhu; Yu Zhao; Alfonso Eirin; Lei Liu; Christopher M Ferguson; Hui Tang; Amir Lerman; Lilach O Lerman
Journal:  Basic Res Cardiol       Date:  2020-01-14       Impact factor: 17.165

3.  Increased tissue angiotensin-converting enzyme activity impairs bradykinin-induced dilation of coronary arterioles in obesity.

Authors:  Attila Feher; James Cassuto; Andras Szabo; Vijay Patel; M Vinayak Kamath; Zsolt Bagi
Journal:  Circ J       Date:  2013-04-20       Impact factor: 2.993

4.  Advanced glycation end products facilitate the proliferation and reduce early apoptosis of cardiac microvascular endothelial cells via PKCβ signaling pathway: Insight from diabetic cardiomyopathy.

Authors:  Yi Luan; Jiefang Zhang; Min Wang; Guosheng Fu; Wenbin Zhang
Journal:  Anatol J Cardiol       Date:  2020-02       Impact factor: 1.596

5.  Long-term prognostic value of macrophage migration inhibitory factor in ST-segment elevation myocardial infarction patients with metabolic syndrome after percutaneous coronary intervention.

Authors:  Xiao-Lin Yu; Qian Zhao; Fen Liu; Yu-Juan Yuan; Bin-Bin Fang; Xue-He Zhang; Wen-Ling Li; Xiao-Mei Li; Guo-Li Du; Xiao-Ming Gao; Yi-Ning Yang
Journal:  Front Cardiovasc Med       Date:  2022-08-11

6.  Acute insulin resistance in ST-segment elevation myocardial infarction in non-diabetic patients is associated with incomplete myocardial reperfusion and impaired coronary microcirculatory function.

Authors:  Danijela Trifunovic; Sanja Stankovic; Dragana Sobic-Saranovic; Jelena Marinkovic; Marija Petrovic; Dejan Orlic; Branko Beleslin; Marko Banovic; Bosiljka Vujisic-Tesic; Milan Petrovic; Ivana Nedeljkovic; Jelena Stepanovic; Ana Djordjevic-Dikic; Milorad Tesic; Nina Djukanovic; Olga Petrovic; Olga Vasovic; Emilija Nestorovic; Jelena Kostic; Arsen Ristic; Miodrag Ostojic
Journal:  Cardiovasc Diabetol       Date:  2014-04-05       Impact factor: 9.951

7.  Impaired Fasting Glucose Is the Major Determinant of the 20-Year Mortality Risk Associated With Metabolic Syndrome in Nondiabetic Patients With Stable Coronary Artery Disease.

Authors:  Arwa Younis; Ronen Goldkorn; Ilan Goldenberg; Diklah Geva; Boaz Tzur; Anna Mazu; Anan Younis; Zvi Fisman; Alexander Tannenbaum; Robert Klempfner
Journal:  J Am Heart Assoc       Date:  2017-10-27       Impact factor: 5.501

8.  Cerebral microvascular dysfunction in metabolic syndrome is exacerbated by ischemia-reperfusion injury.

Authors:  Nathalie Obadia; Marcos Adriano Lessa; Anissa Daliry; Raquel Rangel Silvares; Fabiana Gomes; Eduardo Tibiriçá; Vanessa Estato
Journal:  BMC Neurosci       Date:  2017-09-08       Impact factor: 3.288

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.